ACADIA Pharmaceuticals Inc.  

(Public, NASDAQ:ACAD)   Watch this stock  
Find more results for ACAD
31.96
+1.59 (5.24%)
Mar 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 30.41 - 32.12
52 week 15.64 - 46.48
Open 30.41
Vol / Avg. 2.17M/2.72M
Mkt cap 3.20B
P/E     -
Div/yield     -
EPS -0.94
Shares 100.05M
Beta 2.98
Inst. own 97%
Jun 1, 2015
ACADIA Pharmaceuticals Annual Shareholder Meeting (Estimated) Add to calendar
May 4, 2015
Q1 2015 ACADIA Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 11, 2015
ACADIA Pharmaceuticals Updates Planned Timing of NUPLAZIDTM NDA Submission Conference Call - Webcast
Mar 10, 2015
ACADIA Pharmaceuticals Inc at ROTH Conference
Mar 3, 2015
ACADIA Pharmaceuticals Inc at Cowen Health Care Conference
Feb 26, 2015
Q4 2014 ACADIA Pharmaceuticals Inc Earnings Call - Webcast
Feb 26, 2015
Q4 2014 ACADIA Pharmaceuticals Inc Earnings Release
Jan 13, 2015
ACADIA Pharmaceuticals Inc at JPMorgan Healthcare Conference - Q&A Session
Jan 13, 2015
ACADIA Pharmaceuticals Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -59095.83% -77062.50%
Operating margin -59487.50% -77691.66%
EBITD margin - -77520.00%
Return on average assets -34.10% -35.94%
Return on average equity -35.56% -37.62%
Employees 97 -
CDP Score - -

Address

SUITE 100, 11085 TORREYANA ROAD
SAN DIEGO, CA 92121
United States - Map
+1-858-5582871 (Phone)
+1-858-5582872 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ACADIA Pharmaceuticals Inc. (ACAD) is a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in neurological and related central nervous system disorders. It has a pipeline of product candidates led by NUPLAZID (pimavanserin), which is in Phase III development as a treatment for Parkinson's disease psychosis.

Officers and directors

Leslie L. Iversen Ph.D. Independent Chairman of the Board
Age: 76
Bio & Compensation  - Reuters
Stephen R. Davis Interim Chief Executive Officer
Age: 54
Bio & Compensation  - Reuters
Roger G. Mills M.D. Executive Vice President - Development, Chief Medical Officer
Age: 56
Bio & Compensation  - Reuters
Terrence O. Moore Executive Vice President, Chief Commercial Officer
Age: 59
Bio & Compensation  - Reuters
Glenn F. Baity Vice President, General Counsel, Secretary
Age: 44
Bio & Compensation  - Reuters
Daniel B. Soland Director
Age: 54
Bio & Compensation  - Reuters
Stephen R. Biggar M.D., Ph.D. Independent Director
Age: 43
Bio & Compensation  - Reuters
Michael T. Borer Independent Director
Age: 55
Bio & Compensation  - Reuters
Laura A. Brege Independent Director
Age: 57
Bio & Compensation  - Reuters
Mary A. Gray Ph.D. Independent Director
Age: 61
Bio & Compensation  - Reuters